NEW YORK, Sept. 17 — Agilent and Incyte said today that they would expand an existing licensing agreement to enable Agilent to offer a more comprehensive range of catalog and custom microarrays using Incyte’s gene patent portfolio and  genomic  databases. Using Incyte’s LifeSeq products, Agilent said it would develop highly specific cDNA- and oligonucleotide-based microarrays. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.